Bridge Investment Fund

Bucketfeet is a direct-to-consumer shoe brand that allows artists to create shoe designs and prints them on sneakers once ordered online. Each pair of BucketFeet is designed by a different artist. Find curated inspiration that connects you with the artists that design them. It collaborates with a global community of artists to design limited-edition shoes with the goal of sparking meaningful conversations to create a brighter world. Through a responsive commerce model, Bucketfeet is disrupting traditional manufacturing cycles and redefining the $300B footwear industry, letting the company community select styles they’d like to purchase and wear to help inform demand. It empowers artists to share their stories and perspectives using the universal language of art and the shoe as their canvas. Bucketfeet was founded in 2011 by Raaja Nemani and Aaron Firestein and is headquartered in Chicago, Illinois, USA.

EarlySense develops signal-processing technology. The company's lead product, EverOn, a contact-free early detection patient supervision system that measures, records, displays, and alerts heart and respiration rates, as well as bed entries and exits, patient motion, and quality of sleep from under the mattress. EarlySense Ltd. was founded in 2004 and is based in Ramat Gan, Israel with a research and development facility in Israel; and marketing offices in Boston, Massachusetts.

EarlySense develops signal-processing technology. The company's lead product, EverOn, a contact-free early detection patient supervision system that measures, records, displays, and alerts heart and respiration rates, as well as bed entries and exits, patient motion, and quality of sleep from under the mattress. EarlySense Ltd. was founded in 2004 and is based in Ramat Gan, Israel with a research and development facility in Israel; and marketing offices in Boston, Massachusetts.

Navotek Medical develops real-time innovative tracking and navigation solutions for medical applications. The first application is in the oncology field, providing tumor localization and tracking for optimal radiation therapy. Navotek’s solution will allow for safer and more effective treatment, improving the chances of tumor eradication and decreasing the rate of complications. In addition, it will potentially improve the efficiency of the treatment procedure by shortening individual sessions as well as entire treatment courses. This will increase the radiation rooms’ throughput which will translate into increased earnings for the hospital.

CritiSense was founded in 2004 on the basis of the assets of an earlier company named Vital Medical. The company's device, the Critiview, was developed by the company's co-founder and chief scientist, Professor Avraham Mayevsky, formerly head of the department of Department of Life Sciences and Dean of the Faculty of Natural Sciences at Bar Ilan University, where he established a center for tissue physiology. It provides continuous, real-time multi-parametric physiological data at the tissue and cellular level, by monitoring the mitochondrial function and the microcirculatory blood flow and oxygen saturation, by way of tissue titration therapy with an optical sensor.